Global Epigenetics Market - Segmented by Kits, Reagents, Enzymes, Instruments, Application, Technology, and Geography - Growth, Trends, and Forecast (2018 - 2023)

  • ID: 4520151
  • Report
  • Region: Global
  • 113 pages
  • Mordor Intelligence
1 of 4

FEATURED COMPANIES

  • ABCAM PLC
  • ACTIVE MOTIFF
  • DIAGENODE INC
  • ILLUMINA INC
  • MERCK & CO.
  • QIAGEN
  • MORE
The global epigenetics market is estimated to grow rapidly at a CAGR of over 20% during the forecast period. Epigenetics is defined as the study of changes in gene expression, which are caused by certain base pairs in DNA, or RNA, being turned off or on again, through the chemical reactions.

Increasing Incidence and Prevalence of Cancer

According to Cancer Research UK, in 2012, 14.1 million new cases of cancer were diagnosed worldwide. The World Health Organization estimated that this figure may rise to 35 million new cases in 2035. It is also estimated that nearly 550,000 new cases are diagnosed with head and neck cancer each year, across the world. It is estimated that nearly 6% of the malignancies occur in the United States. According to the American Cancer society, nearly 40,000 people in the United States are diagnosed with head and neck cancer, of which 12,000 were supposed to die in the year 2014 alone. This depicts the large patient pool of cancer patients, which will propel the growth of the epigenetics market. The other factors, like increasing funding for R&D in healthcare and the rising epigenetic applications in non-oncology diseases, are driving the market.

Rising Cost of Instruments

The epigenetic instruments cost is rising gradually, and this increase is becoming one of the major restrains for the growth of the market. The instruments, such as mass spectrometers, sonicators, and the next generation sequences, are already costly, and the rising cost of these instruments are going to increase the cost for the genetic test, which simultaneously decreases the adoption rate of epigenetics. And the lack of skilled researchers is restraining the market growth of epigenetics.

The United States has the Highest Market Share

In North America, the United States is dominating the epigenetics market due to the factors, such as increasing prevalence rate of cancer, increasing funding for the R&D, and the increasing collaborations between several large pharmaceutical companies for development of enhanced therapeutics. Asia-Pacific is expected to record a substantial growth over the forecast period.

Key Developments in the Market
  • December 2017: Roche and Ignyta made definitive merger agreement
  • December 2017: Zymo Research collaborated with Bertin
Major Players: ABCAM PLC, ACTIVE MOTIFF, DIAGENODE INC, ILLUMINA INC, MERCK & CO., QIAGEN, SIGMA ALDRICH CORPORATION, THERMO FISHER SCIENTIFIC, ZYMO RESEARCH CORPORATION, and ROCHE, amongst others

Reasons to Purchase the Report
  • Current and future market outlook for epigenetics in the developed and emerging markets
  • Analyze various perspectives on the market, with the help of Porter’s five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness the fastest growth, during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • 3-month analyst support, along with the market estimate sheet (in excel)
Customization of the Report

This report can be customized to meet your requirements. Please contact us for more information.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ABCAM PLC
  • ACTIVE MOTIFF
  • DIAGENODE INC
  • ILLUMINA INC
  • MERCK & CO.
  • QIAGEN
  • MORE
1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Incidence and Prevalence of Cancer
6.1.2 Increasing Funding for R&D in Healthcare
6.1.3 Rising Epigenetic Applications in Non-Oncology Diseases
6.2 Market Restraints
6.2.1 Rising Cost of Instruments
6.2.2 Dearth of Skilled Researchers
6.3 Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 Segmentation -by Kits
7.1.1 Bisulfite Conversion Kits
7.1.2 Chip-seq Kits
7.1.3 RNA Sequencing Market
7.1.4 Whole Genome Amplification Market
7.1.5 5-HMC and 5-MC Analysis Kits
7.1.6 Other Kits
7.2 Segmentation -by Reagents
7.2.1 Antibodies
7.2.2 Buffers
7.2.3 Histones
7.2.4 Magnetic Beads
7.2.5 Primers
7.2.6 Other Reagents
7.3 Segmentation -by Enzymes
7.3.1 DNA - Modifying Enzymes
7.3.2 Protein Modifying Enzymes
7.3.3 RNA Modifying Enzymes
7.4 Segmentation -by Instruments
7.4.1 Mass Spectrometer
7.4.2 Sonicators
7.4.3 Next Generation Sequencers
7.4.4 Others
7.5 Segmentation -by Application
7.5.1 Oncology
7.5.2 Non-Oncology
7.5.2.1 Inflammatory Diseases
7.5.2.2 Metabolic Diseases
7.5.2.3 Infectious Diseases
7.5.2.4 Cardiovascular Diseases
7.5.2.5 Others
7.5.3 Developmental Biology
7.5.4 Other Research Areas
7.6 Segmentation -by Technology
7.6.1 DNA Methylation
7.6.2 Histone Methylation
7.6.3 Histone Acetylation
7.6.4 Large Noncoding RNA
7.6.5 MicroRNA modification
7.6.6 Chromatin Structures
7.7 Segmentation - by Geography
7.7.1 North America
7.7.1.1 United States
7.7.1.2 Canada
7.7.1.3 Mexico
7.7.2 Europe
7.7.2.1 France
7.7.2.2 Germany
7.7.2.3 United Kingdom
7.7.2.4 Italy
7.7.2.5 Spain
7.7.2.6 Rest of Europe
7.7.3 Asia-Pacific
7.7.3.1 China
7.7.3.2 Japan
7.7.3.3 India
7.7.3.4 Australia
7.7.3.5 New Zealand
7.7.3.6 South Korea
7.7.3.7 Rest of Asia-Pacific
7.7.4 Middle East & Africa
7.7.4.1 GCC
7.7.4.2 South Africa
7.7.4.3 Rest of Middle East & Africa
7.7.5 South America
7.7.5.1 Brazil
7.7.5.2 Argentina
7.7.5.3 Rest of South America

8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches

9. Key Players
9.1 Abcam PLC
9.2 Active Motiff
9.3 Diagenode Inc.
9.4 Illumina Inc.
9.5 Merck & Co.
9.6 Qiagen
9.7 Sigma Aldrich Corporation
9.8 Thermo Fisher Scientific
9.9 Zymo Research Corporation
9.10 Roche
9.11 Others

10. Future of the Market
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • ABCAM PLC
  • ACTIVE MOTIFF
  • DIAGENODE INC
  • ILLUMINA INC
  • MERCK & CO.
  • QIAGEN
  • SIGMA ALDRICH CORPORATION
  • THERMO FISHER SCIENTIFIC
  • ZYMO RESEARCH CORPORATION
  • ROCHE
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll